Hereditary genetic tests and targeted drugs in stage 4 cancer patients

In the early 2000s, targeted cancer drugs directed at genetic targets began to be actively used in cancer treatment, followed in 2011 by immunotherapies, almost changing cancer's fate. However, the use of targeted drugs and immunotherapies often depends on specific conditions and genetic tests.
Next-generation sequencing (NGS) technology has become accessible, bringing more comprehensive tumor genetic sequencing tests into oncology practice and making targeted therapy strategies possible. In cancer, alongside the analysis of somatic / sporadic mutations, distinguishing germline (inherited) mutations is also, in precision oncology, of growing importance.
Research highlighting the importance of hereditary genetic testing at the ASCO 2020 Virtual Congress
A study examining germline / inherited mutations and their potential use as targets for anticancer treatments in patients with advanced cancer was presented at ASCO20. The study analyzed data from 11975 advanced cancer patients who underwent tumor genetic panel testing and secondary germline genetic panel testing at Memorial Sloan Kettering Cancer Center from 2015 to 2019. The MSK-IMPACT genetic testing panel using NGS technology was used. In total, 2043 patients (17.1%) had “likely pathological/pathological (LP/P) germline” variants in cancer predisposition genes, and 11% of these were in genes with high or moderate penetrance.

Potentially targetable variants for treatment were identified in 777 patients (6.5%):
- BRCA 1/2 and Lynch syndrome -associated pathological variants accounted for 53% and 19% of all variants, respectively.
- Patient numbers were: 416 BRCA 1/2
- 149 DNA MMR genes (mismatch repair, Lynch syndrome [LS])
- 122 ATM, 45 PALB2, 26 RAD51 C/D, 7 RET, 4 TSC, 3 PTCH 1, 2 ALK, 1 EGFR, 1 MET, 1 KIT.
The table below shows potential targeted therapies for the germline variants identified in the study and the proportions of cancer patients receiving these treatments.

To determine their usability as treatment targets, recurrent or metastatic disease was identified in 554 patients. Of these patients, 45.3% were found to receive targeted therapy. The rates were 50.9% for BRCA 1/2; 58.3% for LS; 41.7% for PALB2; 36.8% for RAD51 C/D; and 19.3% for ATM. Among patients with BRCA 1/2 variants treated with PARP-I, 55.1% had breast or ovarian cancer. Among patients with PALB2 variants who received PARP-I, 53.3% had breast or pancreatic cancer.
The main message from the study is the need for wider use of germline genetic panels in selecting anticancer treatment for advanced cancer patients and for future studies in this direction.
Related Topic:
- Are multigene tests replacing BRCA tests for breast cancer risk?
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.